Our pharmacokinetic (PK) studies in rats, mice and dogs help in understanding the characteristics of New Chemical entities (NCEs). Our PK studies are highly efficient in predicting the exposure while determining the dosage levels and frequencies for testing in preclinical in vivo animal disease efficacy models. We conduct PK studies for small and large molecules at our state-of-the-art laboratories and vivarium. Our DMPK scientists help understand the drug's AUC, clearance, half-life, the volume of distribution, Cmax, and Cmin in the body over time.
Industry’s leading CRO for Pharmacokinetic Studies A variety of surgical animal PK models Track record of delivering 200+ GLP studies GLP accredited bioanalysis labs for PK studiesNon-GLP bioanalysis facilities for PK studiesA wide range of administration routes
Variety of surgical animal PK models
Track record of delivering 200+ GLP studies
GLP accredited bioanalysis labs for PK studies
Non-GLP bioanalysis facilities for PK studies
A wide range of administration routes
JUNE 28, 2022
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...Read More
JANUARY 04, 2021
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...Read More
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
The characteristic study of pharmacokinetics of drugs in drug development is crucial to ensure its safety and efficacy along with optimizing its ADME properties and other parameters to achieve the desired clinical efficacious candidate.
Pharmacokinetic studies in Aurigene are carried out to assess the potency of the drug compound by examining the parameters on elimination, half-lives, and ADME properties and help scientists to design safer pre clinical and clinical trials.
The standard pharmacokinetic process involves characterizing the potential drug by studying the ADME parameters. Depending upon the single or repeated dose the blood and urine samples are analyzed to determine exposure, dose levels, and preclinical testing.
Pharmacokinetic studies in animals involve validating the necessary parameters on ADME along with clearance studies, half-life, bio availability, volume of distribution, and protein drug interactions.
Pharmacokinetic study validates and ensures the safety and efficacy of drugs during pre-clinical and clinical trials by analyzing the ADME properties. It also provides data regarding drug-drug interactions and the disposition of a drug.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.